uniQure Stock Forecast, Price & News

uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

How has uniQure's stock been impacted by Coronavirus?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QURE stock has decreased by 42.9% and is now trading at $27.14.
View which stocks have been most impacted by COVID-19.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for uniQure.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.05) by $0.26. The biotechnology company earned $2 million during the quarter, compared to analysts' expectations of $2.13 million. uniQure had a net margin of 64.09% and a trailing twelve-month return on equity of 75.59%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.21) EPS.
View uniQure's earnings history.

What price target have analysts set for QURE?

12 analysts have issued 12-month target prices for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they anticipate uniQure's share price to reach $60.15 in the next twelve months. This suggests a possible upside of 121.6% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

• Matt Kapusta, Chief Executive Officer & Executive Director
• Pierre Caloz, Chief Operating Officer
• Christian Klemt, Chief Financial Officer (LinkedIn Profile)
• Ricardo Dolmetsch, President-Research & Development (LinkedIn Profile)
• Maria E. Cantor, Chief Communications Officer

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

Some companies that are related to uniQure include Perrigo (PRGO), Cerevel Therapeutics (CERE), Mawson Infrastructure Group (WIZP), I-Mab (IMAB), Allakos (ALLK), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Karuna Therapeutics (KRTX), Zentalis Pharmaceuticals (ZNTL), 23andMe (ME), ACADIA Pharmaceuticals (ACAD), Arcus Biosciences (RCUS) and Galapagos (GLPG).
View all of QURE's competitors.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.18%), Invesco Ltd. (4.97%), Point72 Asset Management L.P. (1.85%), Bank of New York Mellon Corp (1.81%), 683 Capital Management LLC (1.54%) and Nordea Investment Management AB (1.20%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure.

Which institutional investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Invesco Ltd., Credit Suisse AG, Artisan Partners Limited Partnership, Assenagon Asset Management S.A., International Biotechnology Trust PLC, Verition Fund Management LLC, and Caption Management LLC. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

Which institutional investors are buying uniQure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., 683 Capital Management LLC, Nordea Investment Management AB, Principal Financial Group Inc., Morgan Stanley, Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, and Pacer Advisors Inc..
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $27.14.

How much money does uniQure make?

uniQure has a market capitalization of $1.25 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125.02 million in net income (profit) each year or $6.80 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.